an early stage biopharmaceuticalcompany

Committed topromoting the adoption of BPOC in hospitals across the nation, TTP produces TheunSUMMIT Conference and the online Point of Care forum. For more information,visit http:// Amendola Communications for TerraPharma Project LLCJodi Amendola480-664-8412 ext. Copyright Business Wire 2009. Just five days after publicly declaring that he would definitely be in the market to strengthen the squad during the transfer window, Arsene Wenger is apparently now singing from a different hymn sheet.Since then he has spoken of how his options will be limited in January, even going as far as to mention specific names and seemingly dismiss any hopes that Arsenal fans may have that any of these players might arrive in January.Bordeaux forward Marouane Chamakh was ruled out on the basis that his club would be reluctant to sell despite the fact that they stand to lose him for nothing when his contract expires at the end of the season.Specuation regarding Edin Dzeko, one of the breakout stars of last season and reportedly high on the wish-list of other clubs like Manchester United and AC Milan, was also dismissed on the grounds that he would be too costly despite Wenger admitting to liking him.The hat-trick of dismissals was secured when Wenger then completely rejected the rumours surrounding Inter Milans Mario Ballotelli when saying we are not interested in Mario Ballotelli, you can write that.

Sides that were equally as capable of going into the cauldron of Old Trafford and securing the title in Manchester Uniteds own backyard as they were getting three points from a scrappy 1-0 home win over a relegation-threatened Derby County on a freezing weekday evening.Look at the current European champions Barcelonaas magnificent as the skills possessed by the likes of Xavi, Andres Iniesta, Lionel Messi and Zlatan Ibrahimovic are they are ably supported by the likes of Carles Puyol, Gabriel Milito, Eric Abidal, Seydou Keita, Yaya Toureplayers with experience who are not afraid to get stuck in when it's required.These are qualities that the likes of Manchester United and Chelsea and the rest of the big boys also have in abundance and if Arsenal want to have any chance of being able to compete with them, qualities that they must also acquire.Wengers recent behaviour, such as not shaking the hand of Manchester City manager Mark Hughes following Wednesdays Carling Cup defeat, and his recent statements that Arsenals players must step up, could be a sign that Wengers confidence is beginning to wilt slightly.But it will only take a slight tweak to his undoubtedly admirable footballing philosophy to put Arsenal back amongst the trophiesunfortunately for Wenger however, its something that only an open chequebook can do.. "We are pleased to have Mike and Gary join the Auspex team," said Dr PratikShah, the companys Chairman. "Mikes extensive experience and track record inbuilding companies involved in drug discovery, development, andcommercialization, along with Garys many years as a senior corporate financeexecutive, will be invaluable in leading Auspex in the next phase of itsdevelopment." "Auspex has the earliest and broadest position on the application of deuterationtechnology to validated medicines and has built an attractive pipeline ofpromising drug candidates," said Mike Grey. "The lead program, SD-254, aSelective Serotonin-Norepinephrine Reuptake Inhibitor, has demonstrated inclinical trials an improved profile compared to Effexor XR, the leadingtreatment for depression. Grey was President and CEO of SGXPharmaceuticals, which was recently acquired by Eli Lilly Prior to joining SGX,Mr. Grey was President and CEO of Trega Biosciences, Inc., which was acquired byLION bioscience, AG.

Prior to Trega, he was President of BioChem TherapeuticInc., the pharmaceutical division of BioChem Pharma, Inc., and was President andChief Operating Officer of Ansan, Inc., an early stage biopharmaceuticalcompany. Previously, he served in various roles with Glaxo, including head ofworldwide business development. Prior to Althea, he was CFO forPreventsys, Inc., which was acquired by McAfee He was also CFO of HolocomNetworks, Inc. About Auspex PharmaceuticalsAuspex Pharmaceuticals, founded in 2001, is a clinical stage company developingnext-generation medicines with improved safety and performance. It is a pioneerin the targeted application of deuterium, a naturally occurring, safe and stableisotope of hydrogen, to clinically validated drugs.

The goal of the companystargeted deuteration strategy is to impart greater safety over existing agents,while maintaining or improving efficacy through the judicious use of deuteriumas a replacement for metabolically labile hydrogen atoms. The company hasapplied this targeted deuteration strategy to established drug molecules acrossa wide range of therapeutic areas and has secured a proprietary position on morethan a hundred compounds. The company has built a pipeline of promising drugcandidates and the lead program, SD-254, is being readied for the initiation ofPhase 2 clinical trials for the treatment of depression. The Auspex approach canrapidly generate potential best-in-class therapeutics for significant markets,while reducing the time, cost and risk of drug development. For more informationon Auspex Pharmaceuticals, please visit the company's website at http:// Auspex Pharmaceuticals, Inc.R. Gary Gilmore, 760-599-1800Chief Financial OfficerFax: orKureczka/Martin AssociatesJoan Kureczka, 415-821-2413 (Media)Copyright Business Wire 2009.